Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

Abstract Background In stable patients with type 2 diabetes (T2D), insulin treatment is associated with elevated risk for major adverse cardiovascular events (MACE). Patients with acute coronary syndrome (ACS) and T2D are at particularly high risk for recurrent MACE despite evidence-based therapies....

Full description

Bibliographic Details
Main Authors: Gregory G. Schwartz, Stephen J. Nicholls, Peter P. Toth, Michael Sweeney, Christopher Halliday, Jan O. Johansson, Norman C. W. Wong, Ewelina Kulikowski, Kamyar Kalantar-Zadeh, Henry N. Ginsberg, Kausik K. Ray
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Cardiovascular Diabetology
Subjects:
Acute coronary syndrome
Diabetes
Epigenetics
BET proteins
Online Access:https://doi.org/10.1186/s12933-021-01311-9

Internet

https://doi.org/10.1186/s12933-021-01311-9

Similar Items